EMD-17105

Helical reconstruction
2.4 Å
EMD-17105 Deposition: 11/04/2023
Map released: 21/02/2024
Last modified: 21/02/2024
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links

EMD-17105

AApoAII amyloid fibril Morphology I (ex vivo)

EMD-17105

Helical reconstruction
2.4 Å
EMD-17105 Deposition: 11/04/2023
Map released: 21/02/2024
Last modified: 21/02/2024
Overview 3D View Sample Experiment Validation Volume Browser Additional data Links
Sample Organism: Mus musculus
Sample: AApoAII amyloid fibril
Fitted models: 8oq5 (Avg. Q-score: 0.578)
Raw data: EMPIAR-11525

Deposition Authors: Andreotti G, Schmidt M, Faendrich M
Insights into the Structural Basis of Amyloid Resistance Provided by Cryo-EM Structures of AApoAII Amyloid Fibrils.
PUBMED: 38199491
DOI: doi:10.1016/j.jmb.2024.168441
ISSN: 1089-8638
ASTM: JMOBAK
Abstract:
Amyloid resistance is the inability or the reduced susceptibility of an organism to develop amyloidosis. In this study we have analysed the molecular basis of the resistance to systemic AApoAII amyloidosis, which arises from the formation of amyloid fibrils from apolipoprotein A-II (ApoA-II). The disease affects humans and animals, including SAMR1C mice that express the C allele of ApoA-II protein, whereas other mouse strains are resistant to development of amyloidosis due to the expression of other ApoA-II alleles, such as ApoA-IIF. Using cryo-electron microscopy, molecular dynamics simulations and other methods, we have determined the structures of pathogenic AApoAII amyloid fibrils from SAMR1C mice and analysed the structural effects of ApoA-IIF-specific mutational changes. Our data show that these changes render ApoA-IIF incompatible with the specific fibril morphologies, with which ApoA-II protein can become pathogenic in vivo.